本文由小咖机器人翻译整理

期刊来源：Nat Med

原文链接：https://doi.org/10.1038/s41591-024-03015-5

摘要内容如下：

SELECT试验先前报道，与安慰剂（n=8，801）相比，Semaglutide（n=8，803）可使超重/肥胖和已确诊的心血管疾病患者（无糖尿病）的主要不良心血管事件减少20%。在本研究中，我们在SELECT试验中检测了每周一次的Semaglutide 2.4mg对肾脏结局的影响。与安慰剂（2.2%）相比，semaglutide（1.8%）的预先指定的主要复合肾脏终点（肾脏疾病死亡、开始慢性肾脏替代治疗、出现持续的估计肾小球滤过率（EGFR）<15mlmin-11.73m-2、EGFR持续降低≥50%或出现持续的大量白蛋白尿）的发生率较低：风险比（HR）=0.78；95%可信区间为0.63，0.96；P=0.02。在104周时，EGFR的治疗获益为0.75mlmin-11.73m-2（95%CI 0.43，1.06；P<0.001）和2.19mLmin-11.73m-2（95%CI 1.00，3.38；在基线EGFR<60mlmin-11.73m-2的患者中，P<0.001）。这些结果表明，Semaglutide对超重/肥胖且无糖尿病的个体的肾脏结果有益。ClinicalTrials.gov标识符：NCT03574597。

英文原文如下：

Abstracts

The SELECT trial previously reported a 20% reduction in major adverse cardiovascular events with semaglutide (n = 8,803) versus placebo (n = 8,801) in patients with overweight/obesity and established cardiovascular disease, without diabetes. In the present study, we examined the effect of once-weekly semaglutide 2.4 mg on kidney outcomes in the SELECT trial. The incidence of the pre-specified main composite kidney endpoint (death from kidney disease, initiation of chronic kidney replacement therapy, onset of persistent estimated glomerular filtration rate (eGFR) < 15 ml min-1 1.73 m-2, persistent ≥50% reduction in eGFR or onset of persistent macroalbuminuria) was lower with semaglutide (1.8%) versus placebo (2.2%): hazard ratio (HR) = 0.78; 95% confidence interval (CI) 0.63, 0.96; P = 0.02. The treatment benefit at 104 weeks for eGFR was 0.75 ml min-1 1.73 m-2 (95% CI 0.43, 1.06; P < 0.001) overall and 2.19 ml min-1 1.73 m-2 (95% CI 1.00, 3.38; P < 0.001) in patients with baseline eGFR <60 ml min-1 1.73 m-2. These results suggest a benefit of semaglutide on kidney outcomes in individuals with overweight/obesity, without diabetes.ClinicalTrials.gov identifier: NCT03574597 .

-----------分割线---------

点击链接：https://www.mediecogroup.com/community/user/vip/categories/ ，成为医咖会员，获取12项专属权益。